Society of neuroscience-33rd annual meeting: metabotropic glutamate receptors.
D000818:Animals; D000978:Antiparkinson Agents / Q000494:pharmacology / Q000627:therapeutic use; D001007:Anxiety / Q000188:drug therapy; D004827:Epilepsy / Q000188:drug therapy; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy; D008559:Memantine / Q000494:pharmacology / Q000627:therapeutic use; D018696:Neuroprotective Agents / Q000494:pharmacology; D009488:Neurosciences; D010146:Pain / Q000188:drug therapy; D018094:Receptors, Metabotropic Glutamate / Q000187:drug effects*; D016194:Receptors, N-Methyl-D-Aspartate / Q000187:drug effects; D012958:Societies, Scientific; D019966:Substance-Related Disorders / Q000188:drug therapy; D014481:United States
D000978:Antiparkinson Agents; D018691:Excitatory Amino Acid Antagonists; D018696:Neuroprotective Agents; D018094:Receptors, Metabotropic Glutamate; D016194:Receptors, N-Methyl-D-Aspartate; D008559:Memantine